

Reference number
2268-H

SPECIALTY QUANTITY LIMIT PROGRAM

ENBREL (etanercept)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Enbrel (etanercept) 25 mg per 0.5 mL prefilled syringe	8 syringes per 28 days	RA/PsA/AS <ul style="list-style-type: none"> • 50 mg every week PsO <ul style="list-style-type: none"> • Loading dose: 50 mg twice a week for 3 months • Maintenance dose: 50 mg every week Pediatric PsO/PJIA <ul style="list-style-type: none"> • Weight < 63 kg: 0.8 mg per kg every week • Weight ≥ 63 kg: 50 mg every week
Enbrel 25 mg vial	8 vials per 28 days	
Enbrel (etanercept) 50 mg per 1 mL prefilled syringe/cartridge	8 syringes per 28 days	
Enbrel 50 mg SureClick Autoinjector	8 cartridges per 28 days	

Abbreviations: RA = rheumatoid arthritis; PsA = psoriatic arthritis; AS = ankylosing spondylitis; PsO = plaque psoriasis; PJIA = polyarticular juvenile idiopathic arthritis

III. REFERENCE

1. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; October 2019.